BioPharma DiveDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 09-14 23:46:00(美东 11:46)·⟳ 抓取 00:05:27 +19m27s·⚡ 决策 09-15 00:07:43 +2m16s·43.1 天前
Cellectis 终止同种异体 CAR-T 核心管线、转向临床前体内基因编辑，股价盘中暴跌约40%
这是明确的强利空（放弃最接近上市的临床资产、换道临床前项目），但消息在盘前已扩散、常规盘已重定价约40%至历史低点附近；此刻追空等同于在单日崩盘后卖在地板价，剩余下行空间取决于未知的授权条款与现金跑道，且明日有 FOMC 宏观波动，风险收益比不支持新开空单；无任何做多或受益标的。
📄 原文BioPharma Dive↗ 原文
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive…
不做 Cellectis SA（CLLS.US）
强利空方向明确，但盘前已扩散、常规盘已重定价约40%至历史低位附近，此刻 SHORT 属追崩盘卖地板价，剩余下行高度依赖未知的授权条款与现金跑道，且明日 FOMC 放大波动，风险收益比不足；无做多逻辑或受益标的，故不新开仓，仅保留风险信号供已有多头减仓/禁止新多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Cellectis 终止核心同种异体 CAR-T 管线、转投临床前体内编辑，最近的价值驱动被清零，盘中已暴跌约40%并放量至历史低位。方向明确利空但重定价已基本在当日完成，追空 edge 不足，AVOID，仅保留风险信号。
消息传播链
- 公司官宣战略转型为体内基因编辑公司、终止/寻求合作 lasme-cel 与 eti-cel；官网仅标日期无具体分钟，结合聚合站时间判断为美东盘前前后发布。
- 美东周日晚间已有聚合转载，说明消息在美股盘前已可获得，盘前 CLLS 低见2.07–2.32美元（约-25%）。
- 行业媒体指出公司年初还在宣扬同种异体 CAR-T 动能，转向被视作业内对异体 CAR-T 商业化前景的又一次否定。
- 报道时股价盘中最多跌43%、约2美元，接近历史最低；实时行情确认12:05报1.855美元（-40.2%），量比约4.4倍。市场反应:CLLS 常规盘约1.86美元，较前收3.10美元下跌约40%。
关键理由
- 公司主动终止 lasme-cel/eti-cel 自研开发，II期/BLA 期权价值归零，新管线尚未进人体临床，价值兑现时间表推迟数年。
- 约1.87亿美元市值的小微盘生物科技、股价已在历史低点附近，管线重置后若裁员节流延长跑道，空头缺乏新增量级催化。
主要风险
- 盘前至常规盘已跌约40%（盘前-25%→盘中-40%），利空被快速定价，随时可能因逼空、合作条款超预期或空头回补反弹。
- 明日 FOMC 利率决议与点阵图放大高风险资产波动，小微盘未盈利生物科技双向跳空风险高。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-09-14 · 影响 weakens
官宣与媒体报道均未给出授权首付或现金跑道延长的具体数字；裁员节流可能降低烧钱速度，构成空头的主要抵消项。
检索:Cellectis restructuring cash runway licensing deal lasme-cel eti-cel upfront payment 原文 ↗ - 做空前查反向 · 来源 futu · 日期 2026-09-14 · 影响 invalidates
实时行情显示已跌40%、贴近历史最低、量比4.4倍；在崩盘当日追空，反弹/逼空与超卖修复风险高，剩余 edge 有限。
检索:CLLS 盘中跌幅 成交量 52周低点 逼空风险
先例如何影响了这次决策
对本次决策的影响:未改变标的与方向判断；强化了利空已被快速定价、追空风险收益比差的 AVOID 结论。
方向:未形成可计量的对齐先例面板；生物科技终止核心临床管线并战略转向的事件方向上通常为显著利空，但本次结论不依赖先例幅度。
涨幅量级:不适用：决策为 AVOID，核心依据是当日盘中已完成约40%的重定价，而非先例校准的目标价。
形态:小微盘生物科技单日管线崩盘后常见超跌反弹与高波动，不宜在-40%位置无对冲追空，属机制性常识而非本次回测结论。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 62 ms
{"result": "search_processed_events:agent query=`cellectis exits car-t allogeneic cell therapy restructure in vivo gene editing | cellectis lasme-cel eti-cel strategic partnering heal-101 heal-201`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复 - stock_quote 成功 stock_tools HTTP · 834 ms
{ - direct_instrument_candidates 成功 stock_tools HTTP · 58 ms
{ - web_search 成功 doubao_search · 1,694 ms
豆包搜索结果（原始查询:Cellectis strategic review discontinue allogeneic CAR-T lasme-cel eti-cel in vivo gene editing announcement September 2026；API SearchType:web）
原文全文
展开原文 · 8,390 字
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Dive Brief
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Published Sept. 14, 2026
Jonathan Gardner
Senior Reporter
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
Cellectis will focus resources going forward on "in vivo" gene editing medicines for cardiovascular disease, the company said on Sept. 14, 2026.
Getty Images
Dive Brief:
Cellectis is
giving up on donor-derived cell therapies
and shifting its focus to gene editing medicines, stating in a Monday announcement that the “commercial and clinical landscape” for combatting blood cancers with so-called CAR-T treatments has “changed materially.”
The decision dramatically lengthens Cellectis’ road to a marketed medicine, as the company is ending work on treatments that were in clinical development and turning to therapies that haven’t been tested in humans. One CAR-T program it discovered and out-licensed has advanced as far as Phase 2 testing.
Cellectis claimed that its new strategy represents the “most effective use of its financial and operational resources.” Investors expressed disappointment, however, as company shares fell as much as 43% in morning trading and, at around $2 apiece, trade just above all-time lows.
Dive Insight:
Founded around the turn of the century with gene editing technology developed by Institut Pasteur, Cellectis has long been a frontrunner in advancing “allogeneic” therapies built from the cells of donors. It raised $228 million in an
initial public offering
in 2015 and, since then, has worked to prove its treatments could become a simpler alternative to the complicated, personalized CAR-T therapies now available for multiple blood cancers.
Yet like many of its peers, Cellectis has struggled. Individualized, “autologous” cell therapies have set a high bar for winning approvals in malignancies like leukemia, lymphoma and multiple myeloma. Their allogeneic counterparts have had difficulty matching those results, leading many developers in recent years to
shift resources to other areas
, such as autoimmune disease research.
As recently as early August, Cellectis
was touting data
for two clinical-stage cell therapies called lasme-cel and eti-cel in leukemia and lymphoma. But treatment protocols in many blood cancers have changed drastically as new types of medicines — from cell therapies to bispecific antibodies and more — have been approved. Those developments have heightened Cellectis’ competition, reduced the addressable patient populations for each therapy and slowed study enrollment. “We believe these trends are likely to continue and further constrain the commercial opportunity for both product candidates,” the company said in a statement.
Cellectis will seek “strategic partnering opportunities” to maximize the value of lasme-cel and eti-cel. The company will also “realign its organization” and support existing partnerships with Allogene, Servier, AstraZeneca and Iovance Biotherapeutics, the company said.
The new drugs it’ll work on, meanwhile, are prospective cardiovascular disease treatments that are still in preclinical development. One, called HEAL-101, uses base editing technology to target a gene, APOC3, linked to high triglycerides. Another known as HEAL-201 harnesses an epigenetic editing approach to lower levels of the cholesterol-regulating protein PCSK9. Cellectis will face an uphill battle in both cases, as multiple medications aimed at APOC3 and PCSK9 are already available.
Cellectis’ strategic shift comes in the wake of
multiple recent high-profile failures
in
cardiovascular disease studies
. The latest setback happened just over a week ago, when a therapy from
Novartis
and Ionis Pharmaceuticals fell short in a major study that had widely been expected to succeed.
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
Gene Therapy
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Kevin Frayer via Getty Images
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.
By Ben Fidler •
Updated Sept. 2, 2026
K_E_N via Getty Images
Deep Dive
//
State of Play
Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
By Jacob Bell •
July 1, 2025
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New B…
From Schrödinger, Inc.
September 09, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 G…
From NeuroGT
September 03, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Editors' picks
Kevin Frayer via Getty Images
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.
By Ben Fidler •
Updated Sept. 2, 2026
K_E_N via Getty Images
Deep Dive
//
State of Play
Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
By Jacob Bell •
July 1, 2025
Latest in Gene Therapy
Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing
By Jonathan Gardner
mRNA cancer vaccines’ biggest barriers to market
By Alexandra Pecci
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
By Gwendolyn Wu
The hidden scale-out problem behind CAR-T’s growth
By Sy Mukherjee
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Dive Brief
Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Published Sept. 14, 2026
Jonathan Gardner
Senior Reporter
Share
Copy link
X/Twitter
License
Add us on Google
Cellectis will focus resources going forward on "in vivo" gene editing medicines for cardiovascular disease, the company said on Sept. 14, 2026.
Getty Images
Dive Brief:
Cellectis is
giving up on donor-derived cell therapies
and shifting its focus to gene editing medicines, stating in a Monday announcement that the “commercial and clinical landscape” for combatting blood cancers with so-called CAR-T treatments has “changed materially.”
The decision dramatically lengthens Cellectis’ road to a marketed medicine, as the company is ending work on treatments that were in clinical development and turning to therapies that haven’t been tested in humans. One CAR-T program it discovered and out-licensed has advanced as far as Phase 2 testing.
Cellectis claimed that its new strategy represents the “most effective use of its financial and operational resources.” Investors expressed disappointment, however, as company shares fell as much as 43% in morning trading and, at around $2 apiece, trade just above all-time lows.
Dive Insight:
Founded around the turn of the century with gene editing technology developed by Institut Pasteur, Cellectis has long been a frontrunner in advancing “allogeneic” therapies built from the cells of donors. It raised $228 million in an
initial public offering
in 2015 and, since then, has worked to prove its treatments could become a simpler alternative to the complicated, personalized CAR-T therapies now available for multiple blood cancers.
Yet like many of its peers, Cellectis has struggled. Individualized, “autologous” cell therapies have set a high bar for winning approvals in malignancies like leukemia, lymphoma and multiple myeloma. Their allogeneic counterparts have had difficulty matching those results, leading many developers in recent years to
shift resources to other areas
, such as autoimmune disease research.
As recently as early August, Cellectis
was touting data
for two clinical-stage cell therapies called lasme-cel and eti-cel in leukemia and lymphoma. But treatment protocols in many blood cancers have changed drastically as new types of medicines — from cell therapies to bispecific antibodies and more — have been approved. Those developments have heightened Cellectis’ competition, reduced the addressable patient populations for each therapy and slowed study enrollment. “We believe these trends are likely to continue and further constrain the commercial opportunity for both product candidates,” the company said in a statement.
Cellectis will seek “strategic partnering opportunities” to maximize the value of lasme-cel and eti-cel. The company will also “realign its organization” and support existing partnerships with Allogene, Servier, AstraZeneca and Iovance Biotherapeutics, the company said.
The new drugs it’ll work on, meanwhile, are prospective cardiovascular disease treatments that are still in preclinical development. One, called HEAL-101, uses base editing technology to target a gene, APOC3, linked to high triglycerides. Another known as HEAL-201 harnesses an epigenetic editing approach to lower levels of the cholesterol-regulating protein PCSK9. Cellectis will face an uphill battle in both cases, as multiple medications aimed at APOC3 and PCSK9 are already available.
Cellectis’ strategic shift comes in the wake of
multiple recent high-profile failures
in
cardiovascular disease studies
. The latest setback happened just over a week ago, when a therapy from
Novartis
and Ionis Pharmaceuticals fell short in a major study that had widely been expected to succeed.
Add us on Google
Share
Copy link
X/Twitter
License
Filed Under:
Gene Therapy
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Kevin Frayer via Getty Images
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.
By Ben Fidler •
Updated Sept. 2, 2026
K_E_N via Getty Images
Deep Dive
//
State of Play
Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
By Jacob Bell •
July 1, 2025
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New B…
From Schrödinger, Inc.
September 09, 2026
FDA Approves Tablet Form of Zanubrutinib for All Approved Indications
From BeOne Medicines
September 09, 2026
NeuroGT Announces FDA Clearance of Investigational New Drug Application for NGT-104, an AAV9 G…
From NeuroGT
September 03, 2026
ACTO Achieves Veeva Gold Product Partner Status, Following a Nearly Decade-Long Collaboration …
From ACTO
September 02, 2026
Editors' picks
Kevin Frayer via Getty Images
China competition
Drugs from China are reshaping biotech. Track the licensing deals here.
Including a new deal with Roche last week, Simcere Pharmaceutical has now inked five cross-border licensing pacts since the start of 2025 that are collectively worth up to $5.66 billion.
By Ben Fidler •
Updated Sept. 2, 2026
K_E_N via Getty Images
Deep Dive
//
State of Play
Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
By Jacob Bell •
July 1, 2025
Latest in Gene Therapy
Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing
By Jonathan Gardner
mRNA cancer vaccines’ biggest barriers to market
By Alexandra Pecci
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
By Gwendolyn Wu
The hidden scale-out problem behind CAR-T’s growth
By Sy Mukherjee
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。